NMT Medical, Inc. v. Cardia, Inc.

239 F. App'x 593
CourtCourt of Appeals for the Federal Circuit
DecidedJune 6, 2007
Docket2006-1645
StatusUnpublished
Cited by1 cases

This text of 239 F. App'x 593 (NMT Medical, Inc. v. Cardia, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
NMT Medical, Inc. v. Cardia, Inc., 239 F. App'x 593 (Fed. Cir. 2007).

Opinion

GAJARSA, Circuit Judge.

This is a patent infringement case. Plaintiffs NMT Medical, Inc. and Children’s Medical Center Corporation (collectively “NMT”) are the assignees of U.S. Patent No. 5,451,235 (“the ’235 patent”). The United States District Court for the District of Minnesota granted summary judgment to defendant Cardia, Inc. (“Cardia”) that its accused heart defect repair device did not infringe any of the asserted claims of the ’235 patent. NMT appeals the judgment to this court. Because the district court erred by finding no triable issues of fact as to asserted claims 1-5 and by erroneously construing asserted claim 12, we vacate the summary judgment order and remand for further proceedings.

I. BACKGROUND

A. Technology and patent

This case involves implanted medical devices used to repair heart defects which take the form of holes in the cardiac tissue. One such defect, known as “patent fora-men ovale,” is a congenital flaw in which a small hole between the left and right atria of the heart fails to close following birth. Surgeons apply the devices at issue to correct this flaw using a catheter, thus avoiding open-heart surgery. The patented device consists of two connected “occluders,” flanges that are collapsed inside the catheter but which spring open like an umbrella to a size larger than the defect once the surgeon removes the catheter. To correct the defect, the catheter is inserted into the body via an artery or vein and moved so that it protrudes through the hole to be patched. One occluder is then allowed to open on each side of the defective heart wall, blocking the undesired passage of blood and fixing the device in place. Figure 8c of the ’235 patent illustrates the insertion process:

*595 [[Image here]]

In the figure, the device has been delivered by catheter 190 into a hole in the cardiac tissue. Occluder 12 is open and blocking blood flow on the right side of the hole, and when the catheter is removed, occluder 14 will spring open on the left side.

NMT asserts infringement of six claims of the ’235 patent: Claims 1-5 and Claim 12. Claims 1 and 12 are independent claims, while claims 2 to 5 are dependent on Claim 1. Claim 1 reads as follows:

A device for percutaneous transluminal repair of septal defects comprising:
a) a first occluder having an initial cross sectional configuration smaller than that of the defect to be repaired and a second expanded configuration larger than that of the detect;
b) a second occluder having an initial cross sectional configuration smaller than that of the detect to be repaired and a second expanded configuration larger than that of the defect; and
c) said first occluder and said second occluder being connected by a connector means for fastening the first occluder to the second occluder said connector means comprising a pivot means for allowing rotation of the first occluder relative to the second occluder when said occluders are in the expanded configuration.

’235 patent eol.10 11.43-59 (emphasis added). Claims 2-5 depend from Claim 1, adding limitations not at issue here. Claim 12 differs from Claim 1 only in its part (c), which reads:

c) said first occluder and said second occluder being connected by a connector means for fastening the first occluder to the second occluder said connector means comprising a ball and collar assembly for allowing relative movement between the first occluder and the second occluder when said occluders are in the expanded configuration, said assembly comprising a collar connected to one of the first and second occluders with an aperture and a pin with a ball fitting connected to the other of the first and second occluders on at least one end thereof wherein a diameter of said ball fitting is larger than a diameter of the aperture in the collar.

’235 patent col.11 11.39-61 (emphasis added).

B. The accused device

Cardia’s accused product works generally as described in the ’235 patent. It also consists of two connected occluders which open to repair holes in cardiac tissue after delivery by catheter. To show noninfringement, Cardia argues that its connector — the part of the accused device that links the two occluders and allows them to flex and move relative to each other — does not embody the relevant limitations of any *596 asserted claim. The following diagram, Figure 8 of Cardia’s U.S. Patent No. 7,087,072, illustrates the basic design of the accused device’s connector, though the figure does not necessarily represent the accused device in all particulars:

[[Image here]]

In Cardia’s product, each occluder is fixed to a pin 74 and 72. On the opposite sides of those pins are ball joints 120 and 180, nestled in sockets 114 and 112 in a central sleeve or collar. The ball joints are larger than the openings 152 and 154, so the pins cannot pull out of the socket, but they can both move within the joint to some extent.

Some of the debate on the issue of infringement relates to the different ways in which the connector will allow the pins to move. The parties identify three different modes of movement, designated by the terms “rotate,” “pivot,” and “translate.” In the sense that the parties use these terms, the two pins of the accused device can independently “rotate” (spin within the socket in a pinwheeling motion) and “pivot” (move up-and-down or side-to-side in a hinge-like motion, like that of a human shoulder joint.) The accused device’s connector allows “translation” (the ball moves deeper into the collar or the reverse) only to a minimal extent, due to manufacturing tolerances.

C. Procedural history

In an order dated August 29, 2006, the district court construed the asserted claims and resolved the parties’ cross-motions for summary judgment in favor of Cardia, concluding that there was no infringement.

Claim 1 recites a “connector means ... comprising a pivot means.” The district court used and construed the two phrases “connector means” and “pivot means” interchangeably, determining them to be a means-plus-function limitation pursuant to 35 U.S.C. § 112, 116. Construction of a means-plus-function claim limitation requires the court to identify the claimed function and then to locate structure in the specification which has been clearly linked to that function. See Golight, Inc. v. WalMart Stores, Inc., 355 F.3d 1327, 1333-34 (Fed.Cir.2004). Accordingly, the district court determined that the claimed function was to allow the pins to rotate and pivot (again, in the sense that those terms are used by the parties.) Cardia had argued that another claimed function was to prevent the pins from translating, but the district court refused to impose that function upon the claim. The district court then identified as corresponding structure the embodiments illustrated by Figs.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
239 F. App'x 593, Counsel Stack Legal Research, https://law.counselstack.com/opinion/nmt-medical-inc-v-cardia-inc-cafc-2007.